×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
LOGC – contextlogic inc. - class a (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
LOGC
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/9
09:28 am
logc
ContextLogic Third Quarter 2024 Earnings: US$0.038 loss per share (vs US$3.35 loss in 3Q 2023) [Yahoo! Finance]
Medium
Report
ContextLogic Third Quarter 2024 Earnings: US$0.038 loss per share (vs US$3.35 loss in 3Q 2023) [Yahoo! Finance]
11/7
04:15 pm
logc
ContextLogic Inc. Reports Third-Quarter 2024 Financial Results [Yahoo! Finance]
Low
Report
ContextLogic Inc. Reports Third-Quarter 2024 Financial Results [Yahoo! Finance]
11/7
04:10 pm
logc
ContextLogic Inc. Reports Third-Quarter 2024 Financial Results
Low
Report
ContextLogic Inc. Reports Third-Quarter 2024 Financial Results
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/19
04:48 pm
logc
Form 4 ContextLogic Inc. For: Nov 15 Filed by: Just Brett
Low
Report
Form 4 ContextLogic Inc. For: Nov 15 Filed by: Just Brett
11/7
04:22 pm
logc
Form 10-Q ContextLogic Inc. For: Sep 30
Low
Report
Form 10-Q ContextLogic Inc. For: Sep 30
11/7
04:15 pm
logc
Form 8-K ContextLogic Inc. For: Nov 04
Low
Report
Form 8-K ContextLogic Inc. For: Nov 04
10/23
06:08 pm
logc
Form 144 ContextLogic Inc. Filed by: Forster Joanna
Medium
Report
Form 144 ContextLogic Inc. Filed by: Forster Joanna
9/26
05:28 pm
logc
Form 8-K ContextLogic Inc. For: Sep 24
Low
Report
Form 8-K ContextLogic Inc. For: Sep 24
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/17
LogicBio Therapeutics Inc (NASDAQ: LOGC) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $20.00 price target on the stock.
31.5%
2/11 EQUITY ALERT: ROSEN, NATIONAL INVESTOR COUNSEL, Announces Investigation of Securities Claims Against LogicBio Therapeutics, Inc. – LOGC 14.6%
4/29 Form DEF 14A LogicBio Therapeutics, For: Jun 19 10.9%
2/18 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LogicBio Therapeutics, Inc. - LOGC 10.8%
3/18 EQUITY ALERT: ROSEN, NATIONAL TRIAL COUNSEL, Files First Securities Class Action Lawsuit Against LogicBio Therapeutics, Inc. – LOGC 9.6%
8/13 Q2/2019 6/30/2019 EPS -0.450 ZacksConsensus -0.410 ActVsEst (0.040) - Miss 8.0%
4/23 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LogicBio Therapeutics, Inc. - LOGC 6.1%
3/23 ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds LogicBio Therapeutics, Inc. Investors of Important Deadline in Securities Class Action Commenced by the Firm – LOGC 6.0%
6/27 Form 8-K LogicBio Therapeutics, For: Jun 25 4.8%
8/29 Form 4 LogicBio Therapeutics, For: Aug 27 Filed by: Wilton Thomas 4.4%
2/11 EQUITY ALERT: ROSEN, NATIONAL INVESTOR COUNSEL, Announces Investigation of Securities Claims Against LogicBio Therapeutics, Inc. – LOGC 14.6%
4/29 Form DEF 14A LogicBio Therapeutics, For: Jun 19 10.9%
2/18 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LogicBio Therapeutics, Inc. - LOGC 10.8%
3/18 EQUITY ALERT: ROSEN, NATIONAL TRIAL COUNSEL, Files First Securities Class Action Lawsuit Against LogicBio Therapeutics, Inc. – LOGC 9.6%
8/13 Q2/2019 6/30/2019 EPS -0.450 ZacksConsensus -0.410 ActVsEst (0.040) - Miss 8.0%
4/23 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LogicBio Therapeutics, Inc. - LOGC 6.1%
3/23 ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds LogicBio Therapeutics, Inc. Investors of Important Deadline in Securities Class Action Commenced by the Firm – LOGC 6.0%
6/27 Form 8-K LogicBio Therapeutics, For: Jun 25 4.8%
8/29 Form 4 LogicBio Therapeutics, For: Aug 27 Filed by: Wilton Thomas 4.4%
TOP News Decliners
2/10
LogicBio Therapeutics Provides Update on FDA Review of Investigational New Drug Application for LB-001 for Methylmalonic Acidemia
-32.0%
8/13 Form 10-Q LogicBio Therapeutics, For: Jun 30 -15.7%
8/13 LogicBio up 20% ahead of IND filing for lead gene therapy candidate [Seeking Alpha] -11.9%
3/19 Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against LogicBio Therapeutics, Inc. (LOGC) -11.3%
3/27 LOGICBIO THERAPEUTICS, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey against LogicBio Therapeutics, Inc -11.2%
8/10 LogicBio Therapeutics Inc (NASDAQ: LOGC) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -10.7%
8/23 LogicBio Therapeutics Inc (NASDAQ: LOGC) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -10.2%
4/25 ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds LogicBio Therapeutics, Inc. Investors of the Important Deadline in Securities Class Action First Filed by Firm – LOGC -10.1%
2/21 LogicBio Therapeutics Inc (NASDAQ: LOGC) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -9.2%
6/24 Form 8-K LogicBio Therapeutics, For: Jun 24 -9.0%
8/13 Form 10-Q LogicBio Therapeutics, For: Jun 30 -15.7%
8/13 LogicBio up 20% ahead of IND filing for lead gene therapy candidate [Seeking Alpha] -11.9%
3/19 Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against LogicBio Therapeutics, Inc. (LOGC) -11.3%
3/27 LOGICBIO THERAPEUTICS, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey against LogicBio Therapeutics, Inc -11.2%
8/10 LogicBio Therapeutics Inc (NASDAQ: LOGC) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -10.7%
8/23 LogicBio Therapeutics Inc (NASDAQ: LOGC) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -10.2%
4/25 ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds LogicBio Therapeutics, Inc. Investors of the Important Deadline in Securities Class Action First Filed by Firm – LOGC -10.1%
2/21 LogicBio Therapeutics Inc (NASDAQ: LOGC) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -9.2%
6/24 Form 8-K LogicBio Therapeutics, For: Jun 24 -9.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: